6-K 1 a6189j.htm Q1 2022 RESULTS ANNOUNCEMENT a6189j
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 
 
FORM 6-K
 
 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
April 28, 2022
 
Barclays PLC
(Name of Registrant)
 
1 Churchill Place
London E14 5HP
England
(Address of Principal Executive Office)
 
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F.
 
Form 20-F x Form 40-F
 
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes No x
 
If "Yes" is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b):
 
This Report on Form 6-K is filed by Barclays PLC.
 
This Report comprises:
 
Information given to The London Stock Exchange and furnished pursuant to
General Instruction B to the General Instructions to Form 6-K.
 
 
EXHIBIT INDEX
 


 
 
SIGNATURES
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
BARCLAYS PLC
 
(Registrant)
 
 
 
Date: April 28, 2022
 
 
 
By: /s/ Garth Wright
--------------------------------
 
Garth Wright
 
Assistant Secretary
 
 
 
 
Barclays PLC
 
Q1 2022 Results Announcement
 
31 March 2022
 
Notes
 
This document contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended).
 
The terms Barclays or Group refer to Barclays PLC together with its subsidiaries. Unless otherwise stated, the income statement analysis compares the three months ended 31 March 2022 to the corresponding three months of 2021 and balance sheet analysis as at 31 March 2022 with comparatives relating to 31 December 2021 and 31 March 2021. The abbreviations '£m' and '£bn' represent millions and thousands of millions of Pounds Sterling respectively; the abbreviations '$m' and '$bn' represent millions and thousands of millions of US Dollars respectively; and the abbreviations '€m' and '€bn' represent millions and thousands of millions of Euros respectively.
 
There are a number of key judgement areas, for example impairment calculations, which are based on models and which are subject to ongoing adjustment and modifications. Reported numbers reflect best estimates and judgements at the given point in time.
 
Relevant terms that are used in this document but are not defined under applicable regulatory guidance or International Financial Reporting Standards (IFRS) are explained in the results glossary.
 
The information in this announcement, which was approved by the Board of Directors on 27 April 2022, does not comprise statutory accounts within the meaning of Section 434 of the Companies Act 2006. Statutory accounts for the year ended 31 December 2021, which contained an unmodified audit report under Section 495 of the Companies Act 2006 (which did not make any statements under Section 498 of the Companies Act 2006) have been delivered to the Registrar of Companies in accordance with Section 441 of the Companies Act 2006.
 
These results will be furnished on Form 6-K with the US Securities and Exchange Commission (SEC) as soon as practicable following their publication. Once furnished with the SEC, a copy of the Form 6-K will be available from the SEC's website at www.sec.gov.
 
Barclays is a frequent issuer in the debt capital markets and regularly meets with investors via formal road-shows and other ad hoc meetings. Consistent with its usual practice, Barclays expects that from time to time over the coming quarter it will meet with investors globally to discuss these results and other matters relating to the Group.
 
Non-IFRS performance measures
 
Barclays' management believes that the non-IFRS performance measures included in this document provide valuable information to the readers of the financial statements as they enable the reader to identify a more consistent basis for comparing the businesses' performance between financial periods and provide more detail concerning the elements of performance which the managers of these businesses are most directly able to influence or are relevant for an assessment of the Group. They also reflect an important aspect of the way in which operating targets are defined and performance is monitored by Barclays' management. However, any non-IFRS performance measures in this document are not a substitute for IFRS measures and readers should consider the IFRS measures as well. Refer to the appendix on pages 32 to 36 for further information and calculations of non-IFRS performance measures included throughout this document, and the most directly comparable IFRS measures.
 
Forward-looking statements
 
This document contains certain forward-looking statements within the meaning of Section 21E of the US Securities Exchange Act of 1934, as amended, and Section 27A of the US Securities Act of 1933, as amended, with respect to the Group. Barclays cautions readers that no forward-looking statement is a guarantee of future performance and that actual results or other financial condition or performance measures could differ materially from those contained in the forward-looking statements. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking statements sometimes use words such as 'may', 'will', 'seek', 'continue', 'aim', 'anticipate', 'target', 'projected', 'expect', 'estimate', 'intend', 'plan', 'goal', 'believe', 'achieve' or other words of similar meaning. Forward-looking statements can be made in writing but also may be made verbally by members of the management of the Group (including, without limitation, during management presentations to financial analysts) in connection with this document. Examples of forward-looking statements include, among others, statements or guidance regarding or relating to the Group's future financial position, income growth, assets, impairment charges, provisions, business strategy, capital, leverage and other regulatory ratios, capital distributions (including dividend pay-out ratios and expected payment strategies), projected levels of growth in the banking and financial markets, projected costs or savings, any commitments and targets (including, without limitation, environmental, social and governance (ESG) commitments and targets), estimates of capital expenditures, plans and objectives for future operations, projected employee numbers, IFRS impacts and other statements that are not historical fact. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances. The forward-looking statements speak only as at the date on which they are made. Forward-looking statements may be affected by a number of factors, including, without limitation: changes in legislation, the development of standards and interpretations under IFRS, including evolving practices with regard to the interpretation and application of accounting and regulatory standards, emerging and developing ESG reporting standards, the outcome of current and future legal proceedings and regulatory investigations, future levels of conduct provisions, the policies and actions of governmental and regulatory authorities, the Group's ability along with governments and other stakeholders to measure, manage and mitigate the impacts of climate change effectively, environmental, social and geopolitical risks, and the impact of competition. In addition, factors including (but not limited to) the following may have an effect: capital, leverage and other regulatory rules applicable to past, current and future periods; UK, US, Eurozone and global macroeconomic and business conditions; the effects of any volatility in credit markets; market related risks such as changes in interest rates and foreign exchange rates; effects of changes in valuation of credit market exposures; changes in valuation of issued securities; volatility in capital markets; changes in credit ratings of any entity within the Group or any securities issued by such entities; the direct and indirect consequences of the Russia-Ukraine War on European and global macroeconomic conditions, political stability and financial markets; direct and indirect impacts of the coronavirus (COVID-19) pandemic; instability as a result of the UK's exit from the European Union (EU), the effects of the EU-UK Trade and Cooperation Agreement and the disruption that may subsequently result in the UK and globally; the risk of cyber-attacks, information or security breaches or technology failures on the Group's reputation, business or operations; and the success of future acquisitions, disposals and other strategic transactions. A number of these influences and factors are beyond the Group's control. As a result, the Group's actual financial position, future results, capital distributions, capital, leverage or other regulatory ratios or other financial and non-financial metrics or performance measures or ability to meet commitments and targets may differ materially from the statements or guidance set forth in the Group's forward-looking statements. Additional risks and factors which may impact the Group's future financial condition and performance are identified in Barclays PLC's filings with the SEC (including, without limitation, Barclays PLC's Annual Report on Form 20-F for the fiscal year ended 31 December 2021), which are available on the SEC's website at www.sec.gov.
 
Subject to Barclays' obligations under the applicable laws and regulations of any relevant jurisdiction (including, without limitation, the UK and the US), in relation to disclosure and ongoing information, we undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
 
Performance Highlights
 
Barclays delivered a profit before tax of £2.2bn including £0.5bn of litigation and conduct charges, and a return on tangible equity (RoTE) of 11.5%
 
C. S. Venkatakrishnan, Group Chief Executive, commented
"A strong Q1 performance demonstrated Barclays' ability to deliver broad-based income growth across all operating businesses. Group income was up 10% to £6.5bn, alongside profit before tax of £2.2bn and a RoTE of 11.5%. Our performance includes the relevant costs1 relating to the over-issuance of securities in the US and customer remediation of a legacy loan portfolio. Our income growth was driven partly by Global Markets, which has been helping clients navigate ongoing market volatility caused by geopolitical and economic challenges including the devastating war in Ukraine, and by the impact of higher interest rates in the US and UK.
We remain focused on the impact higher prices are having on our customers and our small business and corporate clients, all of whom are facing far harder conditions this year as a result of inflation, supply chain issues and higher energy costs. We will support them through this difficult period wherever we can, and support the wider economy just as we did through the COVID-19 pandemic.
Our diversified income streams, focus on costs and a Common Equity Tier 1 (CET1) ratio of 13.8% provide a strong platform to deliver our target of a greater than 10% RoTE for 2022. We remain focused on our three strategic priorities as the year progresses: delivering next-generation, digitised consumer financial services, producing sustainable growth in the Corporate and Investment Bank (CIB), and capturing opportunities as we transition to a low-carbon economy."
 
Key financial metrics:
 
 
Income
Cost: income ratio
Profit before tax
RoTE
EPS
CET1
ratio
TNAV per share
Q122
£6.5bn
63%
£2.2bn
11.5%
8.4p
13.8%
294p
 
Q122 performance1:
 
Attributable profit was £1.4bn (Q121: £1.7bn) including litigation and conduct charges net of tax of £0.4bn
Group income was £6.5bn (Q121: £5.9bn) up 10% year-on-year
 
-
Strong CIB income: strong FICC and Equities performance with higher levels of activity as we supported our clients through a period of market volatility, more than offsetting weaker Investment Banking fees driven by a reduced fee pool2
 
-
Consumer and payments businesses recovering: robust UK mortgage lending, positive trends in UK and US consumer spending and payments volumes, and tailwind from rising rates
Costs impacted by litigation and conduct charges: total operating expenses of £4.1bn (Q121: £3.6bn) included litigation and conduct charges of £0.5bn relating to the over-issuance of securities by Barclays Bank PLC in the US and customer remediation costs relating to a legacy loan portfolio
 
-
Group costs excluding litigation and conduct were £3.6bn, up 1% year-on-year
Credit impairment charges: £0.1bn charge (Q121: £0.1bn) driven by low delinquencies and a benign credit environment, with unsecured lending provision levels remaining appropriate in light of inflationary headwinds
Capital: CET1 ratio of 13.8% (December 2021: 15.1%) and tangible net asset value (TNAV) per share of 294p (December 2021: 291p)
 
Outlook:
 
Returns: Barclays continues to target a RoTE of greater than 10% in 2022
Income: Barclays' diversified income streams position the Group well for the current economic and market environment and rising interest rates
Costs: given £0.5bn of litigation and conduct charges in Q122 and current expectations for inflation and performance costs, Barclays now expects FY22 total operating expenses to be around £15.0bn3
Impairment: acknowledging geopolitical uncertainty and cost of living pressures, the impairment charge is expected to remain below pre-pandemic levels in coming quarters given reduced unsecured lending balances and appropriate coverage ratios
Capital: Barclays continues to target a CET1 ratio within the range of 13-14%
Capital returns: Barclays' capital distribution policy incorporates a progressive ordinary dividend, supplemented as appropriate, including with share buybacks. Barclays remains committed to the share buyback programme and the intention would be to launch it as soon as practicable following resolution of filing requirements being reached with the SEC and the appropriate 20-F filings having been made. See Supplementary Information on pages 30 to 31 for further details
 
1
To reflect the over-issuance of US securities under the Barclays Bank PLC US Shelf, 2021 comparatives have been restated. See Basis of preparation on page 31 for further details.
2
Data source: Dealogic for the period covering 1 January to 31 March 2022.
3
Group cost outlook is based on an average USD/GBP FX rate of 1.31 during 2022 and subject to foreign currency movements.
 
Barclays Group results
for the three months ended
 
 
 
31.03.22
31.03.211
 
 
£m
£m
% Change
Net interest income
2,341
1,851
26
Net fee, commission and other income
4,155
4,049
3
Total income
6,496
5,900
10
Credit impairment charges
(141)
(55)
 
Net operating income
6,355
5,845
9
Operating costs
(3,588)
(3,545)
(1)
Litigation and conduct
(523)
(33)
 
Total operating expenses
(4,111)
(3,578)
(15)
Other net (expenses)/income
(10)
132
 
Profit before tax]
2,234
2,399
(7)
Tax charge
(614)
(496)
(24)
Profit after tax
1,620
1,903
(15)
Non-controlling interests
(1)
(4)
75
Other equity instrument holders
(215)
(195)
(10)
Attributable profit
1,404
1,704
(18)
 
 
 
 
Performance measures
 
 
 
Return on average tangible shareholders' equity
11.5%
14.7%
 
Average tangible shareholders' equity (£bn)
48.8
46.5
 
Cost: income ratio
63%
61%
 
Loan loss rate (bps)
15
6
 
Basic earnings per share
8.4p
9.9p
 
Basic weighted average number of shares (m)
16,682
17,293
(4)
Period end number of shares (m)
16,762
17,223
(3)
 
 
 
 
 
As at 31.03.22
Restated2
As at 31.12.21
As at 31.03.21
Balance sheet and capital management
£bn
£bn
£bn
Loans and advances at amortised cost
371.7
361.5
345.8
Loans and advances at amortised cost impairment coverage ratio
1.5%
1.6%
2.2%
Total assets
1,496.1
1,384.3
1,379.7
Deposits at amortised cost
546.5
519.4
498.8
Tangible net asset value per share
294p
291p
267p
Common equity tier 1 ratio
13.8%
15.1%
14.6%
Common equity tier 1 capital
45.3
47.3
45.9
Risk weighted assets
328.8
314.1
313.4
UK leverage ratio
5.0%
5.2%
5.0%
UK leverage exposure
1,123.5
1,137.9
1,145.4
Average UK leverage ratio
4.8%
4.9%
4.9%
Average UK leverage exposure
1,179.4
1,229.0
1,174.9
 
 
 
 
Funding and liquidity
 
 
 
Group liquidity pool (£bn)
320
291
290
Liquidity coverage ratio
159%
168%
161%
Loan: deposit ratio
68%
70%
69%
 
1
The income statement comparatives for Q121 are not impacted by the over-issuance of US securities under the Barclays Bank PLC US Shelf. See Basis of preparation on page 31 for further details.
2
31 December 2021 financial and capital metrics have been restated to reflect the over-issuance of US securities under the Barclays Bank PLC US Shelf. See Basis of preparation on page 31 for further details.
 
Group Finance Director's Review
 
Over-issuance of US securities under the Barclays Bank PLC US Shelf: Barclays has a provision of £540m at Q122 relating to this matter, £320m (post-tax impact of £240m) of which was recognised in Q122 and £220m (post-tax impact of £170m) recognised in 2021, see Basis of preparation on page 31 for further details.
 
Group performance
 
Barclays' diversified model delivered a profit before tax of £2,234m (Q121: £2,399m), RoTE of 11.5% (Q121: 14.7%), and earnings per share (EPS) of 8.4p (Q121: 9.9p)
Total income increased to £6,496m (Q121: £5,900m). Barclays UK income increased 5%. Barclays International income increased 10%, with CIB income up 10% and Consumer, Cards and Payments (CC&P) income up 10%
Credit impairment charges of £141m (Q121: £55m) were driven by ongoing flows to delinquency in unsecured lending. Coverage levels remained materially in line with Q421 and were considered appropriate having been assessed against rising inflation and affordability headwinds
Total operating expenses increased to £4,111m (Q121: £3,578m) due to litigation and conduct charges of £523m including a provision in CIB of £320m (post-tax impact of £240m) relating to the over-issuance of securities by Barclays Bank PLC in the US and higher customer remediation costs relating to a legacy loan portfolio in CC&P. This resulted in a cost: income ratio of 63% (Q121: 61%). Costs excluding litigation and conduct increased 1% to £3,588m, reflecting continued investment and business growth, partially offset by lower performance costs and efficiency savings
The effective tax rate (ETR) was 27.5% (Q121: 20.7%). The tax charge included a £346m charge recognised for the re-measurement of the Group's UK deferred tax assets (DTAs) due to the enactment of legislation in Q122 which will result in the UK banking surcharge rate being reduced from 8% to 3% effective from 1 April 2023 (the ETR excluding the impact of this downward re-measurement of UK DTAs was 12.0%). Tax credits relating to adjustments in respect of prior years partially offset the impact of the downward UK DTA re-measurement
Attributable profit was £1,404m (Q121: £1,704m) including litigation and conduct charges net of tax of £405m
Total assets increased to £1,496bn (December 2021: £1,384bn) primarily due to an increase in client and trading activity, and growth in the liquidity pool
TNAV per share increased to 294p (December 2021: 291p1) primarily reflecting 8.4p of EPS, partially offset by net negative reserve movements driven by higher interest rates
 
Barclays UK
 
Profit before tax increased to £594m (Q121: £460m). RoTE was 15.6% (Q121: 12.0%) reflecting the resilience of the business which is well positioned within the current UK operating environment
Total income increased 5% to £1,649m. Net interest income increased 5% to £1,339m with a net interest margin of 2.62% (Q121: 2.54%) primarily driven by the rising interest rate environment in the UK. Net fee, commission and other income increased 5% to £310m
 
-
Personal Banking income increased 11% to £1,022m, driven by rising interest rates and supported by the benefit of strong 2021 mortgage origination
 
-
Barclaycard Consumer UK income decreased 12% to £276m as higher transaction based revenues from improved customer spend volumes were more than offset by lower interest earning lending (IEL) balances. Lower IEL balances were impacted by higher customer repayments and reduced borrowing
 
-
Business Banking income increased 4% to £351m driven by rising interest rates alongside improved transaction based revenues, partially offset by lower government scheme lending income as repayments continue
Credit impairment charges decreased 38% to £48m reflecting lower unsecured lending balances and lower delinquency rates. As at 31 March 2022, 30 and 90 day arrears rates in UK cards were 1.0% (Q121: 1.6%) and 0.3% (Q121: 0.8%) respectively. The credit card and consumer loan businesses maintain appropriate provision levels in light of emerging affordability headwinds, as reflected in a total coverage ratio of 10.6% (December 2021: 10.9%)
Total operating expenses decreased 3% to £1,007m driven by lower operational costs and efficiency savings, partially offset by increased investment spend
Loans and advances to customers at amortised cost decreased 1% in the quarter to £207.3bn as £1.0bn of mortgage growth was more than offset by a £2.3bn decrease in Business Banking balances due to the repayment of government scheme lending and the yield curve impact from rising interest rates on the Education, Social Housing and Local Authority portfolio carrying value
Customer deposits at amortised cost remained broadly stable at £260.3bn, maintaining a strong loan: deposit ratio of 85% (December 2021: 85%)
RWAs remained stable at £72.7bn (December 2021: £72.3bn)
 
1
31 December 2021 financial and capital metrics have been restated to reflect the over-issuance of US securities under the Barclays Bank PLC US Shelf. See Basis of preparation on page 31 for further details.
 
Barclays International
 
Profit before tax decreased 13% to £1,713m with a RoTE of 14.8% (Q121: 17.7%), reflecting a RoTE of 17.1% (Q121: 17.9%) in CIB and (1.5)% (Q121: 16.5%) in CC&P
 
Total income increased to £4,824m (Q121: £4,399m)
 
 
-
CIB income increased 10% to £3,938m reflecting the benefit of a diversified business model
 
 
-
Global Markets income increased 26% to £2,696m driven by strong performances in FICC and Equities, reflecting higher levels of activity as we supported our clients through a period of market volatility. FICC income increased 37% to £1,644m, mainly in macro, and Equities income increased 13% to £1,052m driven by derivatives
 
 
 
-
Investment Banking fees income decreased 25% to £648m due to the reduced fee pool, particularly in Equity capital markets1, and a strong prior year comparative
 
 
 
-
Within Corporate, Transaction banking income increased 19% to £469m driven by deposit balance growth, improved margins and higher payments volumes. Corporate lending income decreased 39% to £125m due to higher costs of hedging and credit protection
 
 
-
CC&P income increased 10% to £886m
 
 
-
International Cards and Consumer Bank income was stable at £538m as higher average cards balances were offset by higher customer acquisition costs
 
 
 
-
Private Bank income increased 20% to £214m, reflecting client balance growth and improved margins
 
 
 
-
Unified Payments income increased 44% to £134m driven by turnover growth following the easing of lockdown restrictions in the past year
 
Credit impairment charges were £101m (Q121: £22m net release) reflecting a continued benign credit environment
 
 
-
CIB credit impairment net release of £33m (Q121: £43m net release) was driven by improvements in the portfolio and limited material single name wholesale loan charges
 
-
CC&P credit impairment charges increased to £134m (Q121: £21m charge) driven by higher unsecured lending balances in US cards. As at 31 March 2022, 30 and 90 day arrears in US cards were 1.6% (Q121: 2.1%) and 0.8% (Q121: 1.2%) respectively. The US cards business continues to maintain appropriate provision levels in light of potential emerging affordability headwinds, as reflected in a total coverage ratio of 10.4% (December 2021: 10.6%)
Total operating expenses increased 23% to £3,018m
 
 
-
CIB total operating expenses increased 19% to £2,239m primarily driven by a £320m provision relating to the expected losses resulting from a rescission offer to repurchase certain securities issuances identified as being in excess of the registered amount. Operating costs increased 2% to £1,921m as investment in talent, systems and technology were partially offset by lower performance costs
 
-
CC&P total operating expenses increased 36% to £779m driven by £195m of litigation and conduct costs, including a provision for higher customer remediation costs relating to a legacy loan portfolio, and higher investment spend reflecting an increase in marketing and costs for existing and new partnerships
RWAs increased to £245.1bn (December 2021: £230.9bn) resulting from regulatory changes that took effect from 1 January 2022, increased client and trading activity within CIB and an increase in respect of short-term hedging arrangements designed to manage the risks of the rescission offer
 
 
Head Office
 
Loss before tax was £73m (Q121: £32m)
Total income was £23m (Q121: £75m expense) which included a one-off gain of £86m from the sale and leaseback of UK data centres, partially offset by hedge accounting, funding costs on legacy capital instruments and treasury items
Total operating expenses were £86m (Q121: £80m)
Other net income was an expense of £18m (Q121: £123m income) driven by a fair value loss in Barclays associate investment holding in the Business Growth Fund
RWAs were £11.0bn (December 2021: £11.0bn)
 
1
Data source: Dealogic for the period covering 1 January to 31 March 2022.
 
Group capital and leverage1
 
The CET1 ratio decreased by 130bps to 13.8% (December 2021: 15.1%) as capital decreased by £2.1bn to £45.3bn and RWAs increased by £14.7bn to £328.8bn
 
-
The expected impact of regulatory change on 1 January 2022 reduced the CET1 ratio by c80bps as CET1 capital decreased £1.7bn and RWAs increased £6.6bn with a further c30bps reduction due to the £1bn buyback announced with FY21 results
 
-
The impact of the over-issuance of securities in the US reduced the CET1 ratio by c20bps due to a £0.2bn (post-tax) increase to the provision reducing CET1 capital and a £2.8bn increase in RWAs reflecting the short-term hedging arrangements designed to manage the risk of the rescission offer
 
-
Excluding the above impacts there was an increase to the CET1 ratio as CET1 capital increased by £0.9bn reflecting profits (excluding the increase in provision for the over-issuance of securities in the US), an accrual toward a FY22 dividend, equity coupons paid, and an increased deduction for prudent valuation adjustments (PVA). This was largely offset by an RWA increase of £5.3bn primarily due to increased client and trading activity within the CIB
The UK leverage ratio decreased to 5.0% (December 2021: 5.2%) primarily due to the decrease in CET1 capital and the £1bn redemption of Additional Tier 1 (AT1) instruments partially offset by a decrease in the leverage exposure of £14.4bn to £1,123.5bn (December 2021: £1,137.9bn)
 
Group funding and liquidity
 
The liquidity pool was £320bn (December 2021: £291bn) and the liquidity coverage ratio remained significantly above the 100% regulatory requirement at 159% (December 2021: 168%), equivalent to a surplus of £115bn (December 2021: £116bn). The increase in the pool was driven by deposit growth and an increase in wholesale funding, which were partly offset by an increase in business funding consumption
Wholesale funding outstanding, excluding repurchase agreements, was £178.1bn (December 2021: £167.5bn). The Group issued £1.4bn equivalent of minimum requirement for own funds and eligible liabilities (MREL) instruments from Barclays PLC (the Parent company) during the year. The Group has a strong MREL position with a ratio of 31.2% of RWAs which is in excess of its regulatory requirement of 28.9%
 
Other matters
 
Over-issuance of US securities under the Barclays Bank PLC US Shelf: as per Barclays' RNS announcement on 28 March 2022, Barclays has commissioned a review by external counsel of the facts and circumstances relating to the matter and is assisting regulators with their inquiries and requests for information. Barclays Bank PLC has elected to make a rescission offer to certain purchasers of the affected securities issued in excess of the registered amount, which is expected to commence during the second quarter of 2022. Barclays remains committed to its structured products business in the US and expects Barclays Bank PLC to file a new shelf registration statement with the SEC, and resume issuance of structured notes, during the second quarter of 2022. The final cost of any rescission offer will be impacted by prevailing market conditions at the date of that offer. Hedges have been put in place to minimise this volatility, but the final impact may differ from the provision reflected at Q122. For further details, please refer to Supplementary Information on pages 30 to 31
Legacy loan portfolio: a customer remediation provision of £181m has been recognised in relation to a legacy timeshare loan portfolio brokered by Azure Services Limited (ASL). The provision represents the best estimate as at Q122. Barclays continues to review complaints regarding legacy partner finance loans, however it is not currently possible to predict the outcome of this review
Absa sale: on 21 April 2022, Barclays sold 63m ordinary shares in Absa Group Limited (7.4% of Absa's issued share capital) at a price of ZAR 164.0 per share, raising aggregate gross sale proceeds of ZAR 10.3bn (£516m2). The sale is expected to result in an increase of approximately 10 basis points to Barclays' CET1 ratio in the second quarter of 2022 primarily due to reduced capital deductions and RWAs, partially offset by a loss on sale of £42m through the income statement
Pensions: during 2019 and 2020, the UK Retirement Fund (UKRF), the Group's main pension scheme, subscribed for non-transferable listed senior fixed rate notes for £1.25bn. As a result of these transactions, the CET1 impact of the UKRF was deferred until 2023, 2024 and 2025 upon maturity of the notes. Following the PRA's statement on 13 April 2022, Barclays is planning to unwind these transactions and to agree the terms and timing of this unwind with the UKRF Trustee as part of the next triennial actuarial valuation as at 30 September 2022. Upon unwind, this would result in a c30bps reduction to the CET1 ratio potentially being accelerated to Q422 from 2023, 2024 and 2025. As at 31 March 2022, the UKRF was in an accounting surplus of £4.4bn on an IAS 19 basis and as at 30 September 2021 was in a funding surplus of £0.6bn. There may also be a pension related reduction in Pillar 2A requirements in 2022 which could partially mitigate the impact of the unwind on the Group surplus capital position
 
1
31 December 2021 financial and capital metrics have been restated to reflect the over-issuance of US securities under the Barclays Bank PLC US Shelf. See Basis of preparation on page 31 for further details.
2
Exchange rate GBP/ZAR 20.04 as of 21 April 2022.
 
Capital distributions
 
Barclays is committed to maintaining an appropriate balance between delivering attractive total cash returns to shareholders, investment in the business and maintaining a strong capital position. Barclays pays a progressive ordinary dividend, taking into account these objectives and the earnings outlook of the Group. The Board will also continue to supplement the ordinary dividends as appropriate, including with share buybacks
In its 28 March 2022 announcement, Barclays indicated that its previously announced £1bn share buyback programme was expected to commence in Q222 following the publication of Q1 results. Barclays' Q1 performance, including a profit before tax of £2.2bn, a RoTE of 11.5% and a CET1 ratio of 13.8% continues to provide a strong platform for returning capital through the previously announced buyback programme. Due to the ongoing discussions with the SEC regarding the potential restatement of the 2021 financial statements included in Barclays PLC's Form 20-F filed with the SEC, Barclays believes that it is prudent to delay the commencement of the buyback programme until those discussions have been concluded. Barclays remains committed to the share buyback programme and the intention would be to launch it as soon as practicable following resolution of filing requirements being reached with the SEC and the appropriate 20-F filings having been made. For further details regarding discussions with the SEC, see Supplementary Information on pages 30 to 31
 
Group targets
 
Barclays continues to target the following over the medium term:
 
Returns: RoTE of greater than 10%
Cost efficiency: cost: income ratio below 60%
Capital adequacy: CET1 ratio in the range of 13-14%
 
Anna Cross, Group Finance Director
 
Results by Business
 
Barclays UK
Three months ended
Three months ended
 
 
31.03.22
31.03.21
 
Income statement information
£m
£m
% Change
Net interest income
1,339
1,281
5
Net fee, commission and other income
310
295
5
Total income
1,649
1,576
5
Credit impairment charges
(48)
(77)
38
Net operating income
1,601
1,499
7
Operating costs
(998)
(1,036)
4
Litigation and conduct
(9)
(3)
 
Total operating expenses
(1,007)
(1,039)
3
Other net income
-
-
 
Profit before tax
594
460
29
Attributable profit
396
298
33
 
 
 
 
 
As at 31.03.22
As at 31.12.21
As at 31.03.21
Balance sheet information
£bn
£bn
£bn
Loans and advances to customers at amortised cost
207.3
208.8
205.7
Total assets
317.2
321.2
309.1
Customer deposits at amortised cost
260.3
260.6
247.5
Loan: deposit ratio
85%
85%
88%
Risk weighted assets
72.7
72.3
72.7
Period end allocated tangible equity
10.1
10.0
10.0
 
 
 
 
 
Three months ended
Three months ended
 
Performance measures
31.03.22
31.03.21
 
Return on average allocated tangible equity
15.6%
12.0%
 
Average allocated tangible equity (£bn)
10.1
9.9
 
Cost: income ratio
61%
66%
 
Loan loss rate (bps)
9
14
 
Net interest margin
2.62%
2.54%
 
 
Analysis of Barclays UK
Three months ended
Three months ended
 
31.03.22
31.03.21
 
Analysis of total income
£m
£m
% Change
Personal Banking
1,022
923
11
Barclaycard Consumer UK
276
315
(12)
Business Banking
351
338
4
Total income
1,649
1,576
5
 
 
 
 
Analysis of credit impairment charges
 
 
 
Personal Banking
21
(22)
 
Barclaycard Consumer UK
(44)
(36)
(22)
Business Banking
(25)
(19)
(32)
Total credit impairment charges
(48)
(77)
38
 
 
 
 
 
As at 31.03.22
As at 31.12.21
As at 31.03.21
Analysis of loans and advances to customers at amortised cost
£bn
£bn
£bn
Personal Banking
166.5
165.4
160.4
Barclaycard Consumer UK
8.4
8.7
8.7
Business Banking
32.4
34.7
36.6
Total loans and advances to customers at amortised cost
207.3
208.8
205.7
 
 
 
 
Analysis of customer deposits at amortised cost
 
 
 
Personal Banking
196.6
196.4
186.0
Barclaycard Consumer UK
-
-
0.1
Business Banking
63.7
64.2
61.4
Total customer deposits at amortised cost
260.3
260.6
247.5
 
Barclays International
Three months ended
Three months ended1
 
 
31.03.22
31.03.21
 
Income statement information
£m
£m
% Change
Net interest income
936
748
25
Net trading income
2,446
1,934
26
Net fee, commission and other income
1,442
1,717
(16)
Total income
4,824
4,399
10
Credit impairment (charges)/releases
(101)
22
 
Net operating income
4,723
4,421
7
Operating costs
(2,505)
(2,438)
(3)
Litigation and conduct
(513)
(21)
 
Total operating expenses
(3,018)
(2,459)
(23)
Other net income
8
9
(11)
Profit before tax
1,713
1,971
(13)
Attributable profit
1,300
1,431
(9)
 
 
 
 
 
As at 31.03.22
As at 31.12.21
As at 31.03.21
Balance sheet information
£bn
£bn
£bn
Loans and advances at amortised cost
144.8
133.8
123.5
Trading portfolio assets
134.1
146.9
131.1
Derivative financial instrument assets
288.8
261.5
269.4
Financial assets at fair value through the income statement
203.8
188.2
197.5
Cash collateral and settlement balances
132.0
88.1
109.7
Other assets
255.5
225.6
221.7
Total assets
1,159.0
1,044.1
1,052.9
Deposits at amortised cost
286.1
258.8
251.2
Derivative financial instrument liabilities
277.2
256.4
260.2
Loan: deposit ratio
51%
52%
49%
Risk weighted assets
245.1
230.9
230.0
Period end allocated tangible equity
35.6
33.2
32.7
 
 
 
 
 
Three months ended
Three months ended
 
Performance measures
31.03.22
31.03.21
 
Return on average allocated tangible equity
14.8%
17.7%
 
Average allocated tangible equity (£bn)
35.1
32.3
 
Cost: income ratio
63%
56%
 
Loan loss rate (bps)
28
(7)
 
Net interest margin
4.15%
3.92%
 
 
1
The income statement comparatives for Q121 are not impacted by the over-issuance of US securities under the Barclays Bank PLC US Shelf. See Basis of preparation on page 31 for further details.
 
Analysis of Barclays International
 
 
 
Corporate and Investment Bank
Three months ended
Three months ended1
 
 
31.03.22
31.03.21
 
Income statement information
£m
£m
% Change
Net interest income
385
270
43
Net trading income
2,450
1,917
28
Net fee, commission and other income
1,103
1,407
(22)
Total income
3,938
3,594
10
Credit impairment releases
33
43
(23)
Net operating income
3,971
3,637
9
Operating costs
(1,921)
(1,886)
(2)
Litigation and conduct
(318)
(1)
 
Total operating expenses
(2,239)
(1,887)
(19)
Other net income
-
1
 
Profit before tax
1,732
1,751
(1)
Attributable profit
1,316
1,263
4
 
 
 
 
 
As at 31.03.22
As at 31.12.21
As at 31.03.21
Balance sheet information
£bn
£bn
£bn
Loans and advances at amortised cost
109.6
100.0
94.3
Trading portfolio assets
134.0
146.7
130.9
Derivative financial instrument assets
288.7
261.5
269.4
Financial assets at fair value through the income statement
203.8
188.1
197.3
Cash collateral and settlement balances
131.2
87.2
108.8
Other assets
222.5
195.8
190.8
Total assets
1,089.8
979.3
991.5
Deposits at amortised cost
214.7
189.4
185.2
Derivative financial instrument liabilities
277.1
256.4
260.2
Risk weighted assets
213.5
200.7
201.3
 
 
 
 
 
Three months ended
Three months ended
 
Performance measures
31.03.22
31.03.21
 
Return on average allocated tangible equity
17.1%
17.9%
 
Average allocated tangible equity (£bn)
30.8
28.2
 
Cost: income ratio
57%
53%
 
 
 
 
 
 
 
 
 
Analysis of total income
£m
£m
% Change
FICC
1,644
1,204
37
Equities
1,052
932
13
Global Markets
2,696
2,136
26
Advisory
185
163
13
Equity capital markets
47
243
(81)
Debt capital markets
416
453
(8)
Investment Banking fees
648
859
(25)
Corporate lending
125
206
(39)
Transaction banking
469
393
19
Corporate
594
599
(1)
Total income
3,938
3,594
10
 
1
The income statement comparatives for Q121 are not impacted by the over-issuance of US securities under the Barclays Bank PLC US Shelf. See Basis of preparation on page 31 for further details.
 
Analysis of Barclays International
 
 
 
Consumer, Cards and Payments
Three months ended
Three months ended
 
 
31.03.22
31.03.21
 
Income statement information
£m
£m
% Change
Net interest income
551
478
15
Net fee, commission, trading and other income
335
327
2
Total income
886
805
10
Credit impairment charges
(134)
(21)
 
Net operating income
752
784
(4)
Operating costs
(584)
(552)
(6)
Litigation and conduct
(195)
(20)
 
Total operating expenses
(779)
(572)
(36)
Other net income
8
8
-
(Loss)/profit before tax
(19)
220
 
Attributable (loss)/profit
(16)
168
 
 
 
 
 
 
As at 31.03.22
As at 31.12.21
As at 31.03.21
Balance sheet information
£bn
£bn
£bn
Loans and advances at amortised cost
35.2
33.8
29.2
Total assets
69.2
64.8
61.4
Deposits at amortised cost
71.4
69.4
66.0
Risk weighted assets
31.6
30.2
28.8
 
 
 
 
 
Three months ended
Three months ended
 
Performance measures
31.03.22
31.03.21
 
Return on average allocated tangible equity
(1.5)%
16.5%
 
Average allocated tangible equity (£bn)
4.3
4.1
 
Cost: income ratio
88%
71%
 
Loan loss rate (bps)
145
27
 
 
 
 
 
Analysis of total income
£m
£m
% Change
International Cards and Consumer Bank
538
533
1
Private Bank
214
179
20
Unified Payments
134
93
44
Total income
886
805
10
 
Head Office
Three months ended
Three months ended
 
 
31.03.22
31.03.21
 
Income statement information
£m
£m
% Change
Net interest income
66
(178)
 
Net fee, commission and other income
(43)
103
 
Total income
23
(75)
 
Credit impairment releases
8
-
 
Net operating income
31
(75)
 
Operating costs
(85)
(71)
(20)
Litigation and conduct
(1)
(9)
89
Total operating expenses
(86)
(80)
(8)
Other net (expenses)/income
(18)
123
 
Loss before tax
(73)
(32)
 
Attributable loss
(292)
(25)
 
 
 
 
 
 
As at 31.03.22
As at 31.12.21
As at 31.03.21
Balance sheet information
£bn
£bn
£bn
Total assets
19.9
19.0
17.7
Risk weighted assets
11.0
11.0
10.7
Period end allocated tangible equity
3.6
5.7
3.3
 
 
 
 
 
Three months ended
Three months ended
 
Performance measures
31.03.22
31.03.21
 
Average allocated tangible equity (£bn)
3.6
4.3
 
 
Performance Management
 
Margins and balances
 
Three months ended 31.03.22
Three months ended 31.03.21
 
Net interest income
Average customer assets
Net interest margin
Net interest income
Average customer assets
Net interest margin
 
£m
£m
%
£m
£m
%
Barclays UK
1,339
207,607
2.62
1,281
204,663
2.54
Barclays International1
867
84,838
4.15
755
78,230
3.92
Total Barclays UK and Barclays International
2,206
292,445
3.06
2,036
282,893
2.92
Other2
135
 
 
(185)
 
 
Total Barclays Group
2,341
 
 
1,851
 
 
 
1
Barclays International margins include the lending related investment bank business.
2
Other includes Head Office and the non-lending related investment bank businesses not included in Barclays International margins.
 
The Group's combined product and equity structural hedge notional as at 31 March 2022 was £238bn (31 March 2021: £192bn), with an average duration of close to 3 years (2021: average duration 2.5 to 3 years). Group net interest income includes gross structural hedge contributions of £378m (Q121: £350m) and net structural hedge contributions of £141m (Q121: £301m). Gross structural hedge contributions represent the absolute level of interest earned from the fixed receipts on the basket of swaps in the structural hedge, while the net structural hedge contributions represent the net interest earned on the difference between the structural hedge rate and prevailing floating rates.
 
Quarterly analysis for Barclays UK and Barclays International
Net interest income
Average customer assets
Net interest margin
Three months ended 31.12.21
£m
£m
%
Barclays UK
1,313
209,064
2.49
Barclays International1
848
81,244
4.14
Total Barclays UK and Barclays International
2,161
290,308
2.95
 
 
 
 
Three months ended 30.09.21
 
 
 
Barclays UK
1,303
207,692
2.49
Barclays International1
783
77,364
4.02
Total Barclays UK and Barclays International
2,086
285,056
2.90
 
 
 
 
Three months ended 30.06.21
 
 
 
Barclays UK
1,305
205,168
2.55
Barclays International1
763
77,330
3.96
Total Barclays UK and Barclays International
2,068
282,498
2.94
 
 
 
 
Three months ended 31.03.21
 
 
 
Barclays UK
1,281
204,663
2.54
Barclays International1
755
78,230
3.92
Total Barclays UK and Barclays International
2,036
282,893
2.92
 
1
Barclays International margins include the lending related investment bank business.
 
Credit Risk
 
Loans and advances at amortised cost by stage
 
The table below presents an analysis of loans and advances at amortised cost by gross exposure, impairment allowance, impairment charge and coverage ratio by stage allocation and business segment as at 31 March 2022. Also included are off-balance sheet loan commitments and financial guarantee contracts by gross exposure, impairment allowance and coverage ratio by stage allocation as at 31 March 2022.
 
Impairment allowance under IFRS 9 considers both the drawn and the undrawn counterparty exposure. For retail portfolios, the total impairment allowance is allocated to the drawn exposure to the extent that the allowance does not exceed the exposure, as expected credit loss (ECL) is not reported separately. Any excess is reported on the liability side of the balance sheet as a provision. For wholesale portfolios, the impairment allowance on the undrawn exposure is reported on the liability side of the balance sheet as a provision.
 
 
Gross exposure
 
Impairment allowance
Net exposure
 
Stage 1
Stage 2
Stage 3
Total
 
Stage 1
Stage 2
Stage 3
Total
As at 31.03.22
£m
£m
£m
£m
 
£m
£m
£m
£m
£m
Barclays UK
158,707
25,003
3,049
186,759
 
221
943
704
1,868
184,891
Barclays International
26,627
2,792
1,574
30,993
 
575
873
795
2,243
28,750
Head Office
3,688
380
691
4,759
 
1
27
347
375
4,384
Total Barclays Group retail
189,022
28,175
5,314
222,511
 
797
1,843
1,846
4,486
218,025
Barclays UK
35,052
1,848
914
37,814
 
142
48
103
293
37,521
Barclays International
102,476
13,271
1,014
116,761
 
195
177
364
736
116,025
Head Office
124
1
22
147
 
-
-
20
20
127
Total Barclays Group wholesale1
137,652
15,120
1,950
154,722
 
337
225
487
1,049
153,673
Total loans and advances at amortised cost
326,674
43,295
7,264
377,233
 
1,134
2,068
2,333
5,535
371,698
Off-balance sheet loan commitments and financial guarantee contracts2
330,717
27,886
1,724
360,327
 
207
275
21
503
359,824
Total3
657,391
71,181
8,988
737,560
 
1,341
2,343
2,354
6,038
731,522
 
 
 
 
 
 
 
 
 
 
 
 
As at 31.03.22
 
Three months ended 31.03.22
 
 
Coverage ratio
 
Loan impairment charge/(release) and loan loss rate
 
 
Stage 1
Stage 2
Stage 3
Total
 
Loan impairment charge/(release)
Loan loss rate
 
 
%
%
%
%
 
£m
bps
 
Barclays UK
0.1
3.8
23.1
1.0
 
 
43
 
9
 
Barclays International
2.2
31.3
50.5
7.2
 
 
128
 
167
 
Head Office
-
7.1
50.2
7.9
 
 
(7)
 
-
 
Total Barclays Group retail
0.4
6.5
34.7
2.0
 
 
164
 
30
 
Barclays UK
0.4
2.6
11.3
0.8
 
 
8
 
9
 
Barclays International
0.2
1.3
35.9
0.6
 
 
(7)
 
-
 
Head Office
-
-
90.9
13.6
 
 
(1)
 
-
 
Total Barclays Group wholesale1
0.2
1.5
25.0
0.7
 
 
-
 
-
 
Total loans and advances at amortised cost
0.3
4.8
32.1
1.5
 
 
164
 
18
 
Off-balance sheet loan commitments and financial guarantee contracts2
0.1
1.0
1.2
0.1
 
 
(42)
 
 
 
Other financial assets subject to impairment3
 
 
 
 
 
 
19
 
 
 
Total4
0.2
3.3
26.2
0.8
 
 
141
 
 
 
 
1
Includes Wealth and Private Banking exposures measured on an individual basis, and excludes Business Banking exposures, including lending under the government backed Bounce Back Loan Scheme (BBLs) of £9.0bn that are managed on a collective basis and reported within Barclays UK Retail. The net impact is a difference in total exposure of £5,199m of balances reported as wholesale loans on page 17 in the Loans and advances at amortised cost by product disclosure.
2
Excludes loan commitments and financial guarantees of £14bn carried at fair value.
3
Other financial assets subject to impairment not included in the table above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income and other assets. These have a total gross exposure of £198.8bn and impairment allowance of £135m. This comprises £7m ECL on £198.5bn Stage 1 assets, £0m on £130m Stage 2 fair value through other comprehensive income assets, cash collateral and settlement balances and £128m on £135m Stage 3 other assets.
4
The loan loss rate is 15bps after applying the total impairment charge of £141m.
 
 
Gross exposure
 
Impairment allowance
Net exposure
 
Stage 1
Stage 2
Stage 3
Total
 
Stage 1
Stage 2
Stage 3
Total
As at 31.12.21
£m
£m
£m
£m
 
£m
£m
£m
£m
£m
Barclays UK
160,695
22,779
2,915
186,389
 
261
949
728
1,938
184,451
Barclays International
25,981
2,691
1,566
30,238
 
603
795
858
2,256
27,982
Head Office
3,735
429
705
4,869
 
2
36
347
385
4,484
Total Barclays Group retail
190,411
25,899
5,186
221,496
 
866
1,780
1,933
4,579
216,917
Barclays UK
35,571
1,917
969
38,457
 
153
43
111
307
38,150
Barclays International
92,341
13,275
1,059
106,675
 
187
192
458
837
105,838
Head Office
542
2
21
565
 
-
-
19
19
546
Total Barclays Group wholesale1
128,454
15,194
2,049
145,697
 
340
235
588
1,163
144,534
Total loans and advances at amortised cost
318,865
41,093
7,235
367,193
 
1,206
2,015
2,521
5,742
361,451
Off-balance sheet loan commitments and financial guarantee contracts2
312,142
34,815
1,298
348,255
 
217
302
23
542
347,713
Total3
631,007
75,908
8,533
715,448
 
1,423
2,317
2,544
6,284
709,164
 
 
 
 
 
 
 
 
 
 
 
 
As at 31.12.21
 
Year ended 31.12.21
 
 
Coverage ratio
 
Loan impairment charge/(release) and loan loss rate
 
 
Stage 1
Stage 2
Stage 3
Total
 
Loan impairment charge/(release)
Loan loss rate
 
 
%
%
%
%
 
£m
bps
 
Barclays UK
0.2
4.2
25.0
1.0
 
 
(227)
 
-
 
Barclays International
2.3
29.5
54.8
7.5
 
 
181
 
60
 
Head Office
0.1
8.4
49.2
7.9
 
 
-
 
-
 
Total Barclays Group retail
0.5
6.9
37.3
2.1
 
 
(46)
 
-
 
Barclays UK
0.4
2.2
11.5
0.8
 
 
122
 
32
 
Barclays International
0.2
1.4
43.2
0.8
 
 
(197)
 
-
 
Head Office
-
-
90.5
3.4
 
 
-
 
-
 
Total Barclays Group wholesale1
0.3
1.5
28.7
0.8
 
 
(75)
 
-
 
Total loans and advances at amortised cost
0.4
4.9
34.8
1.6
 
 
(121)
 
-
 
Off-balance sheet loan commitments and financial guarantee contracts2
0.1
0.9
1.8
0.2
 
 
(514)
 
 
 
Other financial assets subject to impairment3
 
 
 
 
 
 
(18)
 
 
 
Total
0.2
3.1
29.8
0.9
 
 
(653)
 
 
 
 
1
Includes Wealth and Private Banking exposures measured on an individual basis, and excludes Business Banking exposures, including BBLs of £9.4bn that are managed on a collective basis and reported within Barclays UK Retail. The net impact is a difference in total exposure of £5,994m of balances reported as wholesale loans on page 17 in the Loans and advances at amortised cost by product disclosure.
2
Excludes loan commitments and financial guarantees of £18.8bn carried at fair value.
3
Other financial assets subject to impairment not included in the table above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income and other assets. These have a total gross exposure of £155.2bn and impairment allowance of £114m. This comprises £6m ECL on £154.9bn Stage 1 assets, £1m on £157.0bn Stage 2 fair value through other comprehensive income assets, other assets and cash collateral and settlement balances and £107m on £110m Stage 3 other assets.
 
Loans and advances at amortised cost by product
 
The table below presents a breakdown of loans and advances at amortised cost and the impairment allowance with stage allocation by asset classification.
 
 
 
Stage 2
 
 
As at 31.03.22
Stage 1
Not past due
<=30 days past due
>30 days past due
Total
Stage 3
Total
Gross exposure
£m
£m
£m
£m
£m
£m
£m
Home loans
147,839
18,815
1,370
805
20,990
2,148
170,977
Credit cards, unsecured loans and other retail lending
37,963
5,259
318
454
6,031
2,341
46,335
Wholesale loans
140,872
15,057
948
269
16,274
2,775
159,921
Total
326,674
39,131
2,636
1,528
43,295
7,264
377,233
 
 
 
 
 
 
 
 
Impairment allowance
 
 
 
 
 
 
 
Home loans
18
43
3
7
53
397
468
Credit cards, unsecured loans and other retail lending
759
1,526
116
133
1,775
1,393
3,927
Wholesale loans
357
235
3
2
240
543
1,140
Total
1,134
1,804
122
142
2,068
2,333
5,535
 
 
 
 
 
 
 
 
Net exposure
 
 
 
 
 
 
 
Home loans
147,821
18,772
1,367
798
20,937
1,751
170,509
Credit cards, unsecured loans and other retail lending
37,204
3,733
202
321
4,256
948
42,408
Wholesale loans
140,515
14,822
945
267
16,034
2,232
158,781
Total
325,540
37,327
2,514
1,386
41,227
4,931
371,698
 
 
 
 
 
 
 
 
Coverage ratio
%
%
%
%
%
%
%
Home loans
-
0.2
0.2
0.9
0.3
18.5
0.3
Credit cards, unsecured loans and other retail lending
2.0
29.0
36.5
29.3
29.4
59.5
8.5
Wholesale loans
0.3
1.6
0.3
0.7
1.5
19.6
0.7
Total
0.3
4.6
4.6
9.3
4.8
32.1
1.5
 
 
 
 
 
 
 
 
As at 31.12.21
 
 
 
 
 
 
 
Gross exposure
£m
£m
£m
£m
£m
£m
£m
Home loans
148,058
17,133
1,660
707
19,500
2,122
169,680
Credit cards, unsecured loans and other retail lending
37,840
5,102
300
248
5,650
2,332
45,822
Wholesale loans
132,967
15,246
306
391
15,943
2,781
151,691
Total
318,865
37,481
2,266
1,346
41,093
7,235
367,193
 
 
 
 
 
 
 
 
Impairment allowance
 
 
 
 
 
 
 
Home Loans
19
46
6
7
59
397
475
Credit cards, unsecured loans and other retail lending
824
1,493
85
123
1,701
1,504
4,029
Wholesale Loans
363
248
4
3
255
620
1,238
Total
1,206
1,787
95
133
2,015
2,521
5,742
 
 
 
 
 
 
 
 
Net exposure
 
 
 
 
 
 
 
Home loans
148,039
17,087
1,654
700
19,441
1,725
169,205
Credit cards, unsecured loans and other retail lending
37,016
3,609
215
125
3,949
828
41,793
Wholesale loans
132,604
14,998
302
388
15,688
2,161
150,453
Total
317,659
35,694
2,171
1,213
39,078
4,714
361,451
 
 
 
 
 
 
 
 
Coverage ratio
%
%
%
%
%
%
%
Home loans
-
0.3
0.4
1.0
0.3
18.7
0.3
Credit cards, unsecured loans and other retail lending
2.2
29.3
28.3
49.6
30.1
64.5
8.8
Wholesale loans
0.3
1.6
1.3
0.8
1.6
22.3
0.8
Total
0.4
4.8
4.2
9.9
4.9
34.8
1.6
 
Measurement uncertainty
 
The Q122 ECL provision has been based on macroeconomic indicators used in the Q421 ECL scenario, rolled forward by one quarter, and updated to reflect changes in balances, risk parameters and individually assessed impaired names during the quarter. Management has applied economic uncertainty and other adjustments to modelled ECL outputs.
 
Uncertainty persists. The ongoing geopolitical situation could put further pressure on already high levels of inflation which may weigh on corporate profitability and consumer affordability levels. In addition, COVID-19 infection rates have started to increase across the globe which could result in (among other things) labour shortages and supply chain constraints.
 
In response to the changing economic environment, key baseline macroeconomic indicators have been tracked against consensus updates to March 2022. These latest updates reflect improved UK unemployment expectations but also higher inflationary expectations. However, because the macroeconomic outlook remains uncertain and has only recently changed, these updates have not been reflected in the Q122 ECL modelled provision level.
 
Furthermore, sensitivity analysis has been completed to estimate the impact of applying the refreshed UK unemployment baseline improvement to the UK Credit Cards portfolio. This high level analysis indicated that, all other things being equal, this would result in an immaterial release to modelled ECL. In addition, coverage levels have been assessed in light of the potential impact of higher inflation on customer affordability and expert judgements updated accordingly with the resulting adjustments included within total post model adjustments of £1.3bn (31 December 2021: £1.5bn).
 
The tables below show the key consensus macroeconomic variables used in the Baseline scenario and the probability weights applied to each scenario.
 
Baseline average macroeconomic variables used in the calculation of ECL
 
2022
2023
2024
2025
2026
As at 31.03.22
%
%
%
%
%
UK GDP1
5.7
2.5
2.0
1.8
1.7
UK unemployment2
4.8
4.5
4.4
4.2
4.2
UK HPI3
1.1
1.7
1.9
2.2
2.2
UK bank rate
0.6
1.0
1.0
0.8
0.8
US GDP1
4.3
2.9
2.4
2.4
2.4
US unemployment4
4.3
3.7
3.6
3.6
3.6
US HPI5
4.8
5.3
4.9
5.0
5.0
US federal funds rate
0.3
0.8
1.1
1.3
1.3
 
2021
2022
2023
2024
2025
As at 31.12.21
%
%
%
%
%
UK GDP1
6.2
4.9
2.3
1.9
1.7
UK unemployment2
4.8
4.7
4.5
4.3
4.2
UK HPI3
4.7
1.0
1.9
1.9
2.3
UK bank rate
0.1
0.8
1.0
1.0
0.8
US GDP1
5.5
3.9
2.6
2.4
2.4
US unemployment4
5.5
4.2
3.6
3.6
3.6
US HPI5
11.8
4.5
5.2
4.9
5.0
US federal funds rate
0.2
0.3
0.9
1.2
1.3
 
1
Average Real GDP seasonally adjusted change in year.
2
Average UK unemployment rate 16-year+.
3
Change in year end UK HPI = Halifax All Houses, All Buyers index, relative to prior year end.
4
Average US civilian unemployment rate 16-year+.
5
Change in year end US HPI = FHFA House Price Index, relative to prior year end.
 
Scenario probability weighting
 
Upside 2
Upside 1
Baseline
Downside 1
Downside 2
 
%
%
%
%
%
As at 31.03.22
 
 
 
 
 
Scenario probability weighting
20.9
27.2
30.1
14.8
7.0
As at 31.12.21
 
 
 
 
 
Scenario probability weighting
20.9
27.2
30.1
14.8
7.0
 
Treasury and Capital Risk
 
Regulatory minimum requirements
 
Capital
 
The Group's Overall Capital Requirement for CET1 is 11.0% comprising a 4.5% Pillar 1 minimum, a 2.5% Capital Conservation Buffer (CCB), a 1.5% Global Systemically Important Institution (G-SII) buffer, a 2.5% Pillar 2A requirement and a 0% Countercyclical Capital Buffer (CCyB).
 
The Group's CCyB is based on the buffer rate applicable for each jurisdiction in which the Group has exposures. On 11 March 2020, the Financial Policy Committee (FPC) set the CCyB rate for UK exposures at 0% with immediate effect. The buffer rates set by other national authorities for non-UK exposures are not currently material. Overall, this results in a 0.0% CCyB for the Group. On 13 December 2021, the FPC announced that a CCyB rate of 1% for UK exposures has been re-introduced and will be applicable from 13 December 2022.
 
The Group's Pillar 2A requirement as per the PRA's Individual Capital Requirement was set as a nominal amount. When expressed as a percentage of RWAs this was 4.4% of which at least 56.25% needed to be met with CET1 capital, equating to approximately 2.5% of RWAs. The Pillar 2A requirement is subject to at least annual review and is based on a point in time assessment.
 
Leverage
 
The Group is subject to a UK leverage ratio requirement of 3.8%. This comprises the 3.25% minimum requirement, a G-SII additional leverage ratio buffer (G-SII ALRB) of 0.53% and a countercyclical leverage ratio buffer of 0.0%. Although the leverage ratio is expressed in terms of Tier 1 (T1) capital, 75% of the minimum requirement, equating to 2.4375%, needs to be met with CET1 capital. In addition, the G-SII ALRB must be covered solely with CET1 capital. The CET1 capital held against the 0.53% G-SII ALRB was £5.9bn.
 
The Group is also required to disclose an average UK leverage ratio which is based on capital on the last day of each month in the quarter and an exposure measure for each day in the quarter.
 
MREL
 
The Group is required to meet the higher of: (i) two times the sum of 8% Pillar 1 and 4.4% Pillar 2A; and (ii) 6.75% of leverage exposures.  CET1 capital cannot be counted towards both MREL and the capital buffers, meaning that the buffers will effectively be applied above MREL requirements.
 
Significant regulatory updates in the period
 
Capital and RWAs
 
On 1 January 2022 the PRA's implementation of Basel III standards took effect including the re-introduction of the 100% CET1 capital deduction for qualifying software intangible assets and the introduction of the Standardised Approach for Counterparty Credit Risk (SA-CCR) which replaces the Current Exposure Method (CEM) for Standardised derivative exposures as a more risk sensitive approach. In addition, the PRA also implemented IRB roadmap changes which includes revisions to the criteria for definition of default, probability of default (PD) and loss given default (LGD) estimation to ensure supervisory consistency and increase transparency of IRB models.
 
Leverage
 
From 1 January 2022, UK banks are subject to a single UK leverage ratio requirement meaning that the CRR leverage ratio no longer applies. Central bank claims can be excluded from the UK leverage ratio measure as long as they are matched by qualifying liabilities (rather than deposits).
 
References to CRR, as amended by CRR II mean, unless otherwise specified, CRR as amended by CRR II, as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018.  On 31 March 2022, the temporary transitional powers (TTP) available to UK regulators to delay or phase in on-shoring of European Union legislation into UK law ended with full compliance of the on-shored regulations required from 1 April 2022.
 
 
 
Restated1
Capital ratios2,3,4
As at 31.03.22
As at 31.12.21
CET1
13.8%
15.1%
T1
17.1%
19.1%
Total regulatory capital
20.1%
22.2%
 
 
 
Capital resources
£m
£m
Total equity excluding non-controlling interests per the balance sheet
68,465
69,052
Less: other equity instruments (recognised as AT1 capital)
(11,119)
(12,259)
Adjustment to retained earnings for foreseeable ordinary share dividends
(968)
(666)
Adjustment to retained earnings for foreseeable repurchase of shares
(1,000)
-
Adjustment to retained earnings for foreseeable other equity coupons
(39)
(32)
 
 
 
Other regulatory adjustments and deductions
 
 
Additional value adjustments (PVA)
(1,864)
(1,585)
Goodwill and intangible assets
(8,035)
(6,804)
Deferred tax assets that rely on future profitability excluding temporary differences
(938)
(1,028)
Fair value reserves related to gains or losses on cash flow hedges
3,343
852
Gains or losses on liabilities at fair value resulting from own credit
4
892
Defined benefit pension fund assets
(3,225)
(2,619)
Direct and indirect holdings by an institution of own CET1 instruments
(20)
(50)
Adjustment under IFRS 9 transitional arrangements
601
1,229
Other regulatory adjustments
64
345
CET1 capital
45,269
47,327
 
 
 
AT1 capital
 
 
Capital instruments and related share premium accounts
11,119
12,259
Qualifying AT1 capital (including minority interests) issued by subsidiaries
-
637
Other regulatory adjustments and deductions
(60)
(80)
AT1 capital
11,059
12,816
 
 
 
T1 capital
56,328
60,143
 
 
 
T2 capital
 
 
Capital instruments and related share premium accounts
8,334
8,713
Qualifying T2 capital (including minority interests) issued by subsidiaries
1,540
1,113
Credit risk adjustments (excess of impairment over expected losses)
98
73
Other regulatory adjustments and deductions
(160)
(160)
Total regulatory capital
66,140
69,882
 
 
 
Total RWAs
328,830
314,136
 
1
Capital metrics as at 31 December 2021 have been restated. See Basis of preparation on page 31 for further details. The transitional CET1 ratio remains unchanged at 15.1%.
2
CET1, T1 and T2 capital, and RWAs are calculated applying the transitional arrangements of the CRR as amended by CRR II. This includes IFRS 9 transitional arrangements and the grandfathering of CRR II non-compliant capital instruments. Prior period comparatives include the grandfathering of CRR non-compliant capital instruments.
3
The fully loaded CET1 ratio, as is relevant for assessing against the conversion trigger in Barclays PLC AT1 securities, was 13.6%, with £44.7bn of CET1 capital and £328.6bn of RWAs calculated without applying the transitional arrangements of the CRR as amended by CRR II.
4
The Group's CET1 ratio, as is relevant for assessing against the conversion trigger in Barclays Bank PLC 7.625% Contingent Capital Notes, was 13.8%. For this calculation CET1 capital and RWAs are calculated applying the transitional arrangements under the CRR as amended by CRR II, including the IFRS 9 transitional arrangements. The benefit of the Financial Services Authority (FSA) October 2012 interpretation of the transitional provisions, relating to the implementation of CRD IV, expired in December 2017.
 
 
Restated1
Movement in CET1 capital
Three months ended 31.03.22
 
£m
Opening CET1 capital
47,327
 
 
Profit for the period attributable to equity holders
1,619
Own credit relating to derivative liabilities
(21)
Ordinary share dividends paid and foreseen
(302)
Purchased and foreseeable share repurchase
(1,000)
Other equity coupons paid and foreseen
(222)
Increase in retained regulatory capital generated from earnings
74
 
 
Net impact of share schemes
(268)
Fair value through other comprehensive income reserve
(209)
Currency translation reserve
370
Other reserves
24
Decrease in other qualifying reserves
(83)
 
 
Pension remeasurements within reserves
667
Defined benefit pension fund asset deduction
(606)
Net impact of pensions
61
 
 
Additional value adjustments (PVA)
(279)
Goodwill and intangible assets
(1,231)
Deferred tax assets that rely on future profitability excluding those arising from temporary differences
90
Direct and indirect holdings by an institution of own CET1 instruments
30
Adjustment under IFRS 9 transitional arrangements
(628)
Other regulatory adjustments
(92)
Decrease in regulatory capital due to adjustments and deductions
(2,110)
 
 
Closing CET1 capital
45,269
 
1
Opening balance as at 31 December 2021 has been restated. See Basis of preparation on page 31 for further details.
 
CET1 capital decreased £2.1bn to £45.3bn (December 2021: £47.3bn).
 
CET1 capital decreased by £1.7bn as a result of regulatory changes that took effect from 1 January 2022 including the re-introduction of the 100% CET1 capital deduction for qualifying software intangible assets and a reduction in IFRS9 transitional relief due to the relief applied to the pre-2020 impairment charge reducing to 25% in 2022 from 50% in 2021 and the relief applied to the post-2020 impairment charge reducing to 75% in 2022 from 100% in 2021.
 
£1.6bn of capital generated from profits, after absorbing the £0.2bn (post-tax) additional impact of the over-issuance of securities in the US, was more than offset by distributions of £1.5bn comprising:
 
£1bn for share buybacks announced with FY21 results
£0.3bn accrual towards a FY22 dividend
£0.2bn of equity coupons paid
 
Other significant decreases in the period were:
 
£0.3bn increase in the PVA deduction as a result of increased volatility and uncertainty in the market
£0.2bn decrease in the Fair value through other comprehensive income reserve primarily due to losses on bonds as a result of an increase in yields, partially offset by gains in value of the Absa investment
 
RWAs by risk type and business
 
Credit risk
 
Counterparty credit risk
 
Market Risk
 
Operational risk
Total RWAs
 
STD
IRB
 
STD
IRB
Settlement Risk
CVA
 
STD
IMA
 
 
 
As at 31.03.22
£m
£m
 
£m
£m
£m
£m
 
£m
£m
 
£m
£m
Barclays UK
6,989
54,241
 
229
-
-
57
 
155
-
 
11,047
72,718
Corporate and Investment Bank
35,325
70,831
 
16,422
21,047
268
3,675
 
17,068
23,551
 
25,296
213,483
Consumer, Cards and Payments
21,289
3,459
 
242
12
-
37
 
110
34
 
6,424
31,607
Barclays International
56,614
74,290
 
16,664
21,059
268
3,712
 
17,178
23,585
 
31,720
245,090
Head Office
5,532
6,486
 
-
-
-
-
 
-
-
 
(996)
11,022
Barclays Group
69,135
135,017
 
16,893
21,059
268
3,769
 
17,333
23,585
 
41,771
328,830
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As at 31.12.21
 
 
 
 
 
 
 
 
 
 
 
 
 
Barclays UK
7,195
53,408
 
426
-
-
138
 
100
-
 
11,022
72,289
Corporate and Investment Bank
29,420
64,416
 
15,223
19,238
105
2,289
 
17,306
27,308
 
25,359
200,664
Consumer, Cards and Payments
20,770
2,749
 
215
18
-
21
 
-
57
 
6,391
30,221
Barclays International
50,190
67,165
 
15,438
19,256
105
2,310
 
17,306
27,365
 
31,750
230,885
Head Office
4,733
7,254
 
-
-
-
-
 
-
-
 
(1,025)
10,962
Barclays Group
62,118
127,827
 
15,864
19,256
105
2,448
 
17,406
27,365
 
41,747
314,136
 
Movement analysis of RWAs
 
 
 
 
 
 
Credit risk
Counterparty credit risk
Market risk
Operational risk
Total RWAs
 
£m
£m
£m
£m
£m
Opening RWAs (as at 31.12.21)
189,945
37,673
44,771
41,747
314,136
Book size
10,139
290
(4,236)
24
6,217
Acquisitions and disposals
(70)
-
-
-
(70)
Book quality
(1,239)
(154)
-
-
(1,393)
Model updates
-
-
-
-
-
Methodology and policy
3,278
3,349
-
-
6,627
Foreign exchange movements1
2,099
831
383
-
3,313
Total RWA movements
14,207
4,316
(3,853)
24
14,694
Closing RWAs (as at 31.03.22)
204,152
41,989
40,918
41,771
328,830
 
1
Foreign exchange movements does not include foreign exchange for modelled market risk or operational risk.
 
Overall RWAs increased £14.7bn to £328.8bn (December 2021: £314.1bn)
 
Credit risk RWAs increased £14.2bn:
 
A £10.1bn increase in book size primarily driven by lending activities within CIB and an increase in short-term hedging arrangements designed to manage the risks of the rescission offer, expected to unwind after completion of such rescission offer
A £1.2bn decrease in book quality primarily driven by the benefit in mortgages from an increase in the House Price Index (HPI)
A £3.3bn increase in methodology and policy as a result of regulatory changes that took effect from 1 January 2022, relating to implementation of IRB roadmap changes partially offset by the reversal of the software intangibles benefit
A £2.1bn increase in FX due to appreciation of period end USD and EUR against GBP
 
Counterparty Credit risk RWAs increased £4.3bn:
 
A £3.3bn increase in methodology and policy as a result of regulatory changes that took effect from 1 January 2022, relating to the introduction of SA-CCR
 
Market risk RWAs decreased £3.9bn:
 
A £4.2bn decrease in book size primarily due to a decrease in Stressed Value at Risk (SVaR) model adjustment as a result of changes in portfolio composition and a reduction in Structural FX. This was partially offset by increased client and trading activities.
 
 
 
Restated1
Leverage ratios2,3
As at 31.03.22
As at 31.12.21
£m
£m
Average UK leverage ratio
4.8%
4.9%
Average T1 capital
56,701
59,739
Average UK leverage exposure
1,179,381
1,229,041
 
 
 
UK leverage ratio
5.0%
5.2%
 
 
 
CET1 capital
45,269
47,327
AT1 capital
11,059
12,179
T1 capital
56,328
59,506
 
 
 
UK leverage exposure
1,123,531
1,137,904
 
 
 
UK leverage exposure
 
 
Accounting assets
 
 
Derivative financial instruments
289,822
262,572
Derivative cash collateral
64,836
58,177
Securities financing transactions (SFTs)
186,417
170,853
Loans and advances and other assets
955,020
892,683
Total IFRS assets
1,496,095
1,384,285
 
 
 
Regulatory consolidation adjustments
(3,605)
(3,665)
 
 
 
Derivatives adjustments
 
 
Derivatives netting
(235,071)
(236,881)
Adjustments to collateral
(52,181)
(50,929)
Net written credit protection
19,729
15,509
Potential future exposure (PFE) on derivatives
85,619
137,291
Total derivatives adjustments
(181,904)
(135,010)
 
 
 
SFTs adjustments
29,095
24,544
 
 
 
Regulatory deductions and other adjustments
(22,332)
(20,219)
 
 
 
Weighted off-balance sheet commitments
119,933
115,047
 
 
 
Qualifying central bank claims
(260,196)
(210,134)
 
 
 
Settlement netting
(53,555)
(16,944)
 
 
 
UK leverage exposure
1,123,531
1,137,904
 
1
Capital and leverage metrics as at 31 December 2021 have been restated. See Basis of preparation on page 31 for further details.
2
Capital and leverage measures are calculated applying the transitional arrangements of the CRR as amended by CRR II.
3
Fully loaded average UK leverage ratio was 4.8%, with £56.1bn of T1 capital and £1,178.8bn of leverage exposure. Fully loaded UK leverage ratio was 5.0%, with £55.7bn of T1 capital and £1,122.9bn of leverage exposure. Fully loaded UK leverage ratios are calculated without applying the transitional arrangements of the CRR as amended by CRR II.
 
The UK leverage ratio decreased to 5.0% (December 2021: 5.2%) primarily due to a £3.2bn decrease in T1 capital partially offset by a £14.4bn decrease in the leverage exposure. The UK leverage exposure decreased to £1,123.5bn (December 2021: £1,137.9bn), due to the following movements:
 
£51.7bn decrease in PFE on derivatives primarily driven by increased netting eligibility due to the introduction of SA-CCR
£23.7bn decrease due to a £50.1bn increase in qualifying central bank claims exemption due to the matching of allowable liabilities rather than deposits introduced under the UK leverage framework review, partially offset by a £26.3bn increase in cash
£34.5bn increase in derivative financial instruments post additional regulatory netting and adjustments for cash collateral primarily driven by client and trading activity in CIB and the application of a 1.4 multiplier introduced under SA-CCR
£20.1bn increase in SFTs primarily driven by client activity in CIB
 
The average UK leverage ratio decreased to 4.8% (December 2021: 4.9%) primarily due to a £3.0bn decrease in average T1 capital driven by the redemption of AT1 capital instruments and the reduction of IFRS9 transitional relief. This was partially offset by a £49.7bn decrease in the leverage exposure to £1,179.4bn (December 2021: £1,229.0bn) due to movements broadly in line with UK leverage as well as an increase in net written credit derivatives due to the inclusion of credit default swap options from 1 January 2022.
 
MREL
 
MREL requirements including buffers1,2,3
Total requirement (£m) based on
 
Requirement as a percentage of:
 
 
Restated1
 
 
Restated1
 
As at 31.03.22
As at 31.12.21
 
As at 31.03.22
As at 31.12.21
Requirement based on RWAs (minimum requirement)
94,947
77,302
 
28.9%
24.6%
Requirement based on UK leverage exposure3
89,025
93,975
 
7.9%
6.9%
 
 
 
 
 
 
 
 
 
 
 
Restated1
Own funds and eligible liabilities1,2
 
 
 
As at 31.03.22
As at 31.12.21
 
 
 
 
£m
£m
CET1 capital
 
 
 
45,269
47,327
AT1 capital instruments and related share premium accounts4
 
 
 
11,059
12,179
T2 capital instruments and related share premium accounts4
 
 
 
8,272
8,626
Eligible liabilities
 
 
 
37,886
39,889
Total Barclays PLC (the Parent company) own funds and eligible liabilities
 
 
 
102,486
108,021
 
 
 
 
 
 
Total RWAs
 
 
 
328,830
314,136
Total UK leverage exposure3
 
 
 
1,123,531
1,356,191
 
 
 
 
 
 
 
 
 
 
 
Restated1
Own funds and eligible liabilities ratios as a percentage of:1
 
 
 
As at 31.03.22
As at 31.12.21
Total RWAs
 
 
 
31.2%
34.4%
Total UK leverage exposure3
 
 
 
9.1%
8.0%
 
As at 31 March 2022, Barclays PLC (the Parent company) held £102.5bn of own funds and eligible liabilities equating to 31.2% of RWAs. This was in excess of the Group's MREL requirement to hold £94.9bn of own funds and eligible liabilities equating to 28.9% of RWAs.
 
1
Capital and leverage metrics as at 31 December 2021 have been restated. See Basis of preparation on page 31 for further details.
2
CET1, T1 and T2 capital, and RWAs are calculated applying IFRS 9 transitional arrangements.
3
As at 31 December 2021, MREL requirements were on a CRR leverage basis which, from 1 January 2022, was no longer applicable for UK banks.
4
Includes other AT1 capital regulatory adjustments and deductions of £60m (December 2021: £80m), and other T2 credit risk adjustments and deductions of £62m (December 2021: £81m).
 
Condensed Consolidated Financial Statements
 
Condensed consolidated income statement (unaudited)
 
 
Three months ended 31.03.22
Three months ended 31.03.211
 
 
£m
£m
Total income
 
6,496
5,900
Credit impairment charges
 
(141)
(55)
Net operating income
 
6,355
5,845
Operating expenses excluding litigation and conduct
 
(3,588)
(3,545)
Litigation and conduct
 
(523)
(33)
Operating expenses
 
(4,111)
(3,578)
Other net (expenses)/income
 
(10)
132
Profit before tax
 
2,234
2,399
Tax charge
 
(614)
(496)
Profit after tax
 
1,620
1,903
 
 
 
 
Attributable to:
 
 
 
Equity holders of the parent
 
1,404
1,704
Other equity instrument holders
 
215
195
Total equity holders of the parent
 
1,619
1,899
Non-controlling interests
 
1
4
Profit after tax
 
1,620
1,903
 
 
 
 
Earnings per share
 
p
p
Basic earnings per ordinary share
 
8.4
9.9
 
1
The income statement comparatives for Q121 are not impacted by the over-issuance of US securities under the Barclays Bank PLC US Shelf. See Basis of preparation on page 31 for further details.
 
Condensed consolidated balance sheet (unaudited)
 
 
 
Restated1
 
 
As at 31.03.22
As at 31.12.21
Assets
 
£m
£m
Cash and balances at central banks
 
264,916
238,574
Cash collateral and settlement balances
 
136,289
92,542
Loans and advances at amortised cost
 
371,698
361,451
Reverse repurchase agreements and other similar secured lending
 
2,999
3,227
Trading portfolio assets
 
134,208
147,035
Financial assets at fair value through the income statement
 
207,392
191,972
Derivative financial instruments
 
289,822
262,572
Financial assets at fair value through other comprehensive income
 
61,858
61,753
Investments in associates and joint ventures
 
988
999
Goodwill and intangible assets
 
8,046
8,061
Current tax assets
 
342
261
Deferred tax assets
 
5,171
4,619
Other assets
 
12,366
11,219
Total assets
 
1,496,095
1,384,285
 
 
 
 
Liabilities
 
 
 
Deposits at amortised cost
 
546,482
519,433
Cash collateral and settlement balances
 
121,299
79,371
Repurchase agreements and other similar secured borrowing
 
29,013
28,352
Debt securities in issue
 
110,658
98,867
Subordinated Liabilities
 
11,630
12,759
Trading portfolio liabilities
 
78,092
54,169
Financial liabilities designated at fair value
 
238,913
250,960
Derivative financial instruments
 
277,466
256,883
Current tax liabilities
 
1,050
689
Deferred tax liabilities
 
37
37
Other liabilities
 
12,021
12,724
Total liabilities
 
1,426,661
1,314,244
 
 
 
 
Equity
 
 
 
Called up share capital and share premium
 
4,551
4,536
Other reserves
 
317
1,770
Retained earnings
 
52,478
50,487
Shareholders' equity attributable to ordinary shareholders of the parent
 
57,346
56,793
Other equity instruments
 
11,119
12,259
Total equity excluding non-controlling interests
 
68,465
69,052
Non-controlling interests
 
969
989
Total equity
 
69,434
70,041
 
 
 
 
Total equity and liabilities
 
1,496,095
1,384,285
 
1
See Basis of preparation on page 31 for further details on restatement of prior period comparatives.
 
Condensed consolidated statement of changes in equity (unaudited)
 
 
 
 
Restated1
Restated1
 
Restated1
 
Called up
share capital
and share
premium
Other equity
instruments
Other
reserves
Retained
earnings
Total
Non-
controlling
interests
Total
equity
Three months ended 31.03.22
£m
£m
£m
£m
£m
£m
£m
Balance as at 01 January 2022
4,536
12,259
1,770
50,487
69,052
989
70,041
Profit after tax
-
215
-
1,404
1,619
1
1,620
Retirement benefit remeasurements
-
-
-
667
667
-
667
Other
-
-
(1,462)
-
(1,462)
-
(1,462)
Total comprehensive income for the period
-
215
(1,462)
2,071
824
1
825
Employee share schemes and hedging thereof
15
-
-
351
366
-
366
Issue and redemption of other equity instruments
-
(1,132)
-
25
(1,107)
(20)
(1,127)
Other equity instruments coupon paid
-
(215)
-
-
(215)
-
(215)
Vesting of employee share schemes
-
-
9
(454)
(445)
-
(445)
Dividends paid
-
-
-
-
-
(1)
(1)
Other movements
-
(8)
-
(2)
(10)
-
(10)
Balance as at 31 March 2022
4,551
11,119
317
52,478
68,465
969
69,434
 
1
See Basis of preparation on page 31 for further details on restatement of opening balances.
 
 
As at 31.03.2022
As at 31.12.2021
Other reserves
£m
£m
Currency translation reserve
3,110
2,740
Fair value through other comprehensive income reserve
(492)
(283)
Cash flow hedging reserve
(3,343)
(853)
Own credit reserve
(93)
(960)
Other reserves and treasury shares
1,135
1,126
Total
317
1,770
 
Financial Statement Notes
 
1.      Contingent liabilities and commitments
 
Contingent liabilities are possible obligations whose existence will be confirmed only by uncertain future events and present obligations where the transfer of economic resources is uncertain or cannot be reliably measured. Contingent liabilities are not recognised on the balance sheet but are disclosed unless the likelihood of an outflow of economic resources is remote.
 
Over Issuance of Securities in the US
 
Barclays Bank PLC maintains a US Shelf registration statement with the SEC in order to issue securities to US investors. The current shelf registration statement was declared effective by the SEC and was valid for three years from 1 August 2019. At the time this shelf registration statement was filed, Barclays Bank PLC was not eligible to be a "well-known seasoned issuer" (or WKSI) due to an historic SEC settlement order and was required to pre-register a set amount of securities to be issued under the US Shelf with the SEC.
 
On 10 March 2022, executive management became aware that Barclays Bank PLC had issued securities in excess of the set amount. It has been estimated that the BBPLC US shelf limit was exceeded on or around 18 February 2021, with issuances through to 10 March 2022 exceeding the limit by c.US$15bn. The securities that have been over issued in this period comprise structured notes and exchange traded notes (ETNs). Securities issued in excess of the limit are considered to be "unregistered securities" for the purposes of US securities law with the certain purchasers of those securities having the right to require Barclays Bank PLC to repurchase those securities at their original purchase price with compensatory interest and the potential for the certain purchasers to bring civil claims and the SEC and other regulators to take enforcement actions against Barclays Bank PLC.
 
Barclays has a provision of £540m at Q122 relating to this matter, £320m (post-tax impact of £240m) of which was recognised in Q122 and £220m (post-tax of £170m) recognised in 2021 in relation to the c.US$13bn over issuance of structured notes which represents the best estimate of the rescission right investors have for these securities. A contingent liability exists in relation to the c.US$2bn over issuance of ETNs due to evidentiary challenges and the high level of trading in the securities. A contingent liability also exists in relation to any potential claims or enforcement actions taken against Barclays Bank PLC but there is currently no indication of the timetable for resolution and it is not practicable to provide an estimate of the financial effects. Barclays Bank PLC is unable to assess the likelihood of liabilities that may arise out of any civil claims or enforcement actions. Any such liabilities, claims or actions could have an adverse effect on Barclays Bank PLC's and the Group's business, financial condition, results of operations and reputation as a frequent issuer in the securities markets.
 
Supplementary Information
 
Over-issuance of US securities under the Barclays Bank PLC US Shelf
 
In its announcement on 28 March 2022 relating to the impact of over-issuance under the US shelf registration statement (US Shelf) of Barclays Bank PLC (BBPLC), Barclays indicated that (i) it was assessing the impact of these matters on prior period financial statements of BBPLC and (ii) it had commissioned a review by external counsel (the Review) of the facts and circumstances relating to these matters, including, among other things, the control environment related to such over-issuance. In addition, it disclosed that BBPLC would make a rescission offer to certain purchasers of the affected securities issued in excess of the registered amount under the US Shelf. Since the announcement, Barclays has continued to engage with, and respond to inquiries and requests for information from, various regulators, including the US Securities and Exchange Commission (SEC).
 
Developments since the announcement:
 
Financial Statements in BPLC 2021 ARA: The directors do not believe it is appropriate under UK company law and financial reporting standards to revise the financial statements of Barclays PLC (BPLC) included in its 2021 Annual Report and Accounts (BPLC 2021 ARA) to reflect the impact of the over-issuance, but Barclays will instead record a pre-tax provision of £220m (£170m post-tax) as at 31 December 2021 as a prior year adjustment in the financial statements of BPLC for the year ended 31 December 2022 in relation to these matters. This and subsequent results announcements will therefore also reflect the impact of this adjustment in the appropriate prior year quarters.
 
Financial Statements in BPLC 2021 Form 20-F: Barclays is currently in discussions with the SEC regarding whether the fact that the financial statements of BPLC included in its Annual Report on Form 20-F for the year ended 31 December 2021 (the BPLC 2021 Form 20-F) do not reflect the £220m provision at 31 December 2021 for the over-issuance of structured notes and a contingent liability disclosure in respect of the over-issuance of exchange traded notes (ETNs) and related potential claims and enforcement actions against BBPLC and its affiliates constitutes a material accounting error under US securities laws. Depending on the outcome of those discussions, Barclays may be required to withdraw and refile (Restate or Restatement) the financial statements included in the BPLC 2021 Form 20-F to reflect these matters.  In any event, Barclays will be required to reflect the financial impact of these matters by adjusting the comparative financial periods in its subsequent financial filings until the error has been fully corrected.
 
BBPLC Financial Statements: Similarly, the directors of BBPLC do not believe it is appropriate under UK company law and financial reporting standards, to revise the financial statements of BBPLC included in its 2021 Annual Report and Accounts (BBPLC 2021 ARA), but Barclays will instead record the pre-tax provision of £220m as a prior year adjustment in the financial statements of BBPLC for the year ended 31 December 2022. However, due to the lower applicable materiality threshold for BBPLC, on 27 April 2022 the directors of BBPLC determined that BBPLC would Restate the financial statements included in its Annual Report on Form 20-F for the year ended 31 December 2021 (the BBPLC 2021 20-F) previously filed with the SEC. BBPLC intends to Restate such financial statements to reflect both the provision and the contingent liability referred to above. There will therefore be differences between the 2021 financial statements included in the BBPLC 2021 Form 20-F once amended and the BBPLC 2021 ARA, and investors are therefore cautioned to exercise care in using these financial statements during the course of 2022.
 
Assessment of Control Environment: In light of the ongoing Review, management has concluded that, by virtue of the fact that the over-issuance occurred and was not immediately identified, both BPLC and BBPLC had a material weakness in relation to certain aspects of their internal control environment and, as a consequence, their internal control over financial reporting for the year ended 31 December 2021 was not effective under the applicable Committee of Sponsoring Organizations (COSO) Framework. The material weakness that has been identified relates to a failure to monitor issuances of structured notes and ETNs under BBPLC's US Shelf during the period in which BBPLC's status changed from a "well-known seasoned issuer" to an "ineligible issuer" for US securities law purposes, and BBPLC was required to pre-register a set amount of securities to be issued under its US Shelf with the SEC. As a result of this failure, BBPLC issued securities in excess of that set amount.
 
Amendments to Forms 20-F: BPLC is preparing an amendment to the BPLC 2021 Form 20-F to reflect the change in management's assessment of BPLC's internal control over financial reporting and KPMG's auditor attestation thereon as well as its disclosure controls and procedures. BBPLC is preparing an amendment to the BBPLC 2021 Form 20-F to include its Restated 2021 financial statements and to reflect the change in management's assessment of internal control over financial reporting and disclosure controls and procedures. These amendments will be filed as soon as practicable. Until the BPLC 2021 Form 20-F has been amended to disclose that its internal controls were not effective, KPMG's audit report should not be relied upon by users of BPLC's financial statements. Until BBPLC has Restated its financial statements for the year ended 31 December 2021 and amended the BBPLC 2021 Form 20-F, investors and other users of BBPLC's filings with the SEC are cautioned not to rely on the financial statements included in the BBPLC 2021 Form 20-F.
 
Remediation Plans: Following a review of other issuance programmes utilised by members of the Group, management have determined that the Group is not in excess of any limit applicable to such programmes. Barclays is nonetheless enhancing the internal controls relating to its debt securities issuance activity in all relevant jurisdictions.
 
Barclays remains committed to its structured products business in the US and expects BBPLC to file a new shelf registration statement with the SEC as soon as practicable following the amendment of the BBPLC 2021 Form 20-F. For further details, please refer to the notes to the condensed consolidated financial statements accompanying this Q122 results announcement.
 
Notwithstanding any Restatement of the financial statements included in the BPLC 2021 Form 20-F that may ultimately be required in accordance with the applicable SEC rules, as mentioned above, it is not intended that the financial statements in the BPLC 2021 ARA for the financial year ended 31 December 2021 would be revised and the BPLC 2021 ARA, which has been circulated to shareholders ahead of the BPLC AGM to be held on 4 May 2022, will be laid before shareholders at that meeting in the usual way.
 
Basis of preparation
 
In March 2022, Barclays management became aware that Barclays Bank PLC, a subsidiary undertaking had issued securities in the US in excess of the amount it had registered with the SEC. The securities issued in excess of the registered amount were structured and exchange traded notes. As the securities were not issued in compliance with the Securities Act of 1933, as amended (the "Securities Act"), this gives rise to a right of rescission for certain purchasers of the securities. A proportion of these costs associated with the right of rescission are attributable to the financial statements for the year ended 31 December 2021. This omission in the financial statements has resulted in the restatement of the prior period comparatives with the following impact:
 
-
Litigation and conduct charges in the income statement in relation to 2021 were under reported by £220m increasing total operating expenses from a reported £14,439m to £14,659m. Provisions on the balance sheet have increased from a reported £1,688m to £1,908m.
-
Taxation charge in the income statement has reduced by £50m from a reported £1,188m to £1,138m with a corresponding decrease in current tax liabilities on the balance sheet from £739m to £689m.
-
CET1 capital decreased £0.2bn from £47.5bn to £47.3bn with the CET1 ratio remaining unchanged at 15.1%. The T1 ratio moved from 19.2% to 19.1% and Total capital ratio moved from 22.3% to 22.2%
-
Leverage exposure increased £1.9bn with the UK leverage ratio decreasing from 5.3% to 5.2% and the average UK leverage ratio remaining unchanged at 4.9%
-
Total own funds and eligible liabilities decreased £0.2bn to £108bn, which was in excess of a restated requirement to hold £94bn of own funds and eligible liabilities.
 
The overall impact of the restatement on the 2021 comparatives has been to reduce the reported profit after tax from £7,226m to £7,056m for the full financial year. This reduction in profit after tax was incurred after Q121 and as such, no adjustments have been made to the Q121 reported income statement figures.
 
Reflecting this adjustment in this Q122 results announcement results in a pre-tax provision of £220m (£170m post-tax) being reflected as at 31 December 2021. This reduces the 2022 impact of the provision previously communicated on 28 March 2022 and results in a pre-tax provision of £320m (£240m post-tax) being recognised in Q122. Had such adjustment not been made the impact on the key performance ratios for Q122 would have been to reduce the return on average tangible shareholders equity to 10.1% and increase the cost:income ratio to 67%.
 
Appendix: Non-IFRS Performance Measures
 
The Group's management believes that the non-IFRS performance measures included in this document provide valuable information to the readers of the financial statements as they enable the reader to identify a more consistent basis for comparing the businesses' performance between financial periods, and provide more detail concerning the elements of performance which the managers of these businesses are most directly able to influence or are relevant for an assessment of the Group. They also reflect an important aspect of the way in which operating targets are defined and performance is monitored by management.
 
However, any non-IFRS performance measures in this document are not a substitute for IFRS measures and readers should consider the IFRS measures as well.
 
Non-IFRS performance measures glossary
 
Measure
Definition
Loan: deposit ratio
Loans and advances at amortised cost divided by deposits at amortised cost.
 
Period end allocated tangible equity
Allocated tangible equity is calculated as 13.5% (2021: 13.5%) of RWAs for each business, adjusted for capital deductions, excluding goodwill and intangible assets, reflecting the assumptions the Group uses for capital planning purposes. Head Office allocated tangible equity represents the difference between the Group's tangible shareholders' equity and the amounts allocated to businesses.
 
Average tangible shareholders' equity
Calculated as the average of the previous month's period end tangible equity and the current month's period end tangible equity. The average tangible shareholders' equity for the period is the average of the monthly averages within that period.
 
Average allocated tangible equity
Calculated as the average of the previous month's period end allocated tangible equity and the current month's period end allocated tangible equity. The average allocated tangible equity for the period is the average of the monthly averages within that period.
 
Return on average tangible shareholders' equity
Annualised profit after tax attributable to ordinary equity holders of the parent, as a proportion of average shareholders' equity excluding non-controlling interests and other equity instruments adjusted for the deduction of intangible assets and goodwill. The components of the calculation have been included on pages 33 to 34.
 
Return on average allocated tangible equity
Annualised profit after tax attributable to ordinary equity holders of the parent, as a proportion of average allocated tangible equity. The components of the calculation have been included on pages 33 to 35.
 
Cost: income ratio
Total operating expenses divided by total income.
 
Loan loss rate
Quoted in basis points and represents total annualised impairment charges divided by gross loans and advances held at amortised cost at the balance sheet date. The components of the calculation have been included on page 15. Quoted as zero when credit impairment is a net release.
 
Net interest margin
Annualised net interest income divided by the sum of average customer assets. The components of the calculation have been included on page 14.
 
Tangible net asset value per share
Calculated by dividing shareholders' equity, excluding non-controlling interests and other equity instruments, less goodwill and intangible assets, by the number of issued ordinary shares. The components of the calculation have been included on page 36.
 
Returns
 
Return on average tangible equity is calculated as profit after tax attributable to ordinary equity holders of the parent as a proportion of average tangible equity, excluding non-controlling and other equity interests for businesses. Allocated tangible equity has been calculated as 13.5% (2021: 13.5%) of RWAs for each business, adjusted for capital deductions, excluding goodwill and intangible assets, reflecting the assumptions the Group uses for capital planning purposes. Head Office average allocated tangible equity represents the difference between the Group's average tangible shareholders' equity and the amounts allocated to businesses.
 
 
Profit/(loss) attributable to ordinary equity holders of the parent